OVID — Ovid Therapeutics Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activa… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$2.54
Market Cap$463M
Float161.3M
Shares Outstanding186.6M
P/E (Forward)1.79
Price/Sales (TTM)64.99
vs. Analyst Target+115.4% to analyst PT
Operating Margin (TTM)-670.25%
Revenue (TTM)$7.1M
Dividend RateNone
Analyst Target Price$5.47 (6 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $12.6M -$80.7M $12.6M -$81.1M
2021 $208M $123M $208M $124M
2022 $1.5M -$51.4M $1.5M -$54.2M
2023 $392,000 -$52.3M $392,000 -$57.0M
2024 $566,000 -$26.4M $566,000 -$57.8M
2025 $7.3M -$17.4M $7.0M -$42.1M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $6.3M -$4.7M
Sep 2025 $132,000 -$12.2M
Dec 2025 $718,000 $9.7M
Mar 2026 N/A -$17.0M

Ownership & Float

Insider Ownership7.0%
Institutional Ownership56.4%
Short Float5.3%
% of All Funds Holding1.14%
Number of Funds Holding94

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.60Near-term / short-term trend
Weekly40-Week SMA$1.85Medium-term trend
Weekly80-Week SMA$1.21Cyclical trend (business cycle)
Weekly200-Week SMA$2.03Secular trend (multi-year)
Monthly10-Month SMA$1.81Near-term monthly trend
Monthly20-Month SMA$1.21Medium-term monthly trend
Monthly40-Month SMA$2.02Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.30 support 1.20x 0 months ago
$1.60 support 2.07x 1 months ago
$0.50 support 2.09x 8 months ago
$0.40 support 3.68x 9 months ago
$3.00 resistance 5.96x 22 months ago

Historical Earnings Reactions (37 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.36% 0.00% 43.24% 6.99% -28.02%
1 Day -0.89% -0.43% 45.95% 21.37% -28.02%
1 Week 1.39% 0.00% 43.24% 29.57% -24.82%
2 Weeks 6.56% 1.28% 54.05% 66.19% -33.81%
1 Month 3.82% 1.63% 52.78% 65.04% -75.54%

Next earnings: May 12, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan2.1%44.4%9
Feb-6.6%33.3%9
Mar0.2%44.4%9
Apr13.4%66.7%9
May-4.5%37.5%8
Jun-0.4%44.4%9
Jul10.1%55.6%9
Aug12.1%33.3%9
Sep7.3%44.4%9
Oct-9.9%22.2%9
Nov22.9%66.7%9
Dec-16.2%22.2%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.07% 47.4% 426
Tuesday 0.19% 46.1% 469
Wednesday 0.12% 47.3% 465
Thursday -0.12% 43.8% 457
Friday 0.34% 44.5% 458

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 56.4%

Insider Transactions — Smart Summary

Total insider ownership: 7.0%

Founder-led management: Jeremy Levin (Executive Chairman)

12-Month Insider Activity Summary

Total Filings2
Net Value-$29,285.65
Net Shares Change47,928
% of Float0.0%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
ALEXANDER MARGARET A. President and CEO -$16,901.2 1 N/A
Rona Jeffrey A CBFO -$12,384.45 1 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-02 Rona Jeffrey A CBFO -$12,384.45 Transaction at $1.45, now +75.2%
2026-03-02 ALEXANDER MARGARET A. President and CEO -$16,901.2 Transaction at $1.45, now +75.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Ovid Therapeutics Inc (OVID) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for OVID on Trend Edge →